Cannabinoid Encyclopedia

How research is judged

What does Preclinical evidence mean?

Animal, cellular, biochemical, or mechanistic work that must stay distinct from human outcomes. 1

Also called: animal evidence, animal study, cell study, cellular evidence

Simple definition

Preclinical evidence, in plain English

Animal, cellular, biochemical, or mechanistic work that must stay distinct from human outcomes. 1

Why it matters

How this word is used in cannabinoid research

This term tells you what kind of research you are reading. It helps separate stronger human evidence from early or indirect evidence.

How to read it

Use the term to understand the study, then open the source before drawing a conclusion.

Do not confuse this with

Common questions

Questions people ask

What does Preclinical evidence mean?

Animal, cellular, biochemical, or mechanistic work that must stay distinct from human outcomes.

Why does Preclinical evidence matter?

This term tells you what kind of research you are reading. It helps separate stronger human evidence from early or indirect evidence.

Is Preclinical evidence proof that a cannabinoid works?

No. A definition helps explain the language. The related research pages and their sources show what was actually studied.

Sources

Research connected to this term

Definitions explain the word. These links show research records currently connected with it.

  1. 1
    A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats preclinical PubMed 39528623
  2. 2
    Orally administered Cannabigerol (CBG) in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain. preclinical PubMed 39322049
  3. 3
    The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation. preclinical PubMed 37332213
  4. 4
    Therapeutic Effects of Non-Euphorigenic Cannabis Extracts in Osteoarthritis. preclinical PubMed 35994012
  5. 5
    Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity. preclinical PubMed 34577072
  6. 6
    Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. preclinical PubMed 39921943
See all 56 connected research sources
  1. 1
    A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats preclinical PubMed 39528623
  2. 2
    Orally administered Cannabigerol (CBG) in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain. preclinical PubMed 39322049
  3. 3
    The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation. preclinical PubMed 37332213
  4. 4
    Therapeutic Effects of Non-Euphorigenic Cannabis Extracts in Osteoarthritis. preclinical PubMed 35994012
  5. 5
    Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity. preclinical PubMed 34577072
  6. 6
    Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. preclinical PubMed 39921943
  7. 7
    Determination of Cannabinoids in Meat Products and Animal Feeds in Singapore Using Liquid Chromatography-Tandem Mass Spectrometry. preclinical PubMed 39200508
  8. 8
    Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. preclinical PubMed 35364618
  9. 9
    Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. preclinical PubMed 24282673
  10. 10
    Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin. preclinical PubMed 29588939
  11. 11
    Preclinical safety and efficacy of cannabidivarin for early life seizures. preclinical PubMed 30633929
  12. 12
    The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia. preclinical PubMed 41159452
  13. 13
    Evaluation of Sex Differences in the Potential of Δ9-Tetrahydrocannabinol, Cannabidiol, Cannabidiolic Acid, and Oleoyl Alanine to Reduce Nausea-Induced Conditioned Gaping Reactions in Sprague-Dawley Rats. preclinical PubMed 35984924
  14. 14
    Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea. preclinical PubMed 26439367
  15. 15
    Effect of combined doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague- Dawley) models of conditioned gaping. preclinical PubMed 26381155
  16. 16
    Suppression of lithium chloride-induced conditioned gaping (a model of nausea-induced behaviour) in rats (using the taste reactivity test) with metoclopramide is enhanced by cannabidiolic acid. preclinical PubMed 24012649
  17. 17
    Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. preclinical PubMed 40580638
  18. 18
    Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. preclinical PubMed 37721989
  19. 19
    The antinociceptive activity and mechanism of action of cannabigerol. preclinical PubMed 36916438
  20. 20
    Oral Consumption of Cannabidiol During Pregnancy Alters Behavior in Mouse Offspring. preclinical PubMed 41840986
  21. 21
    Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. preclinical PubMed 34179865
  22. 22
    Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure. preclinical PubMed 30550613
  23. 23
    Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products. preclinical PubMed 36603937
  24. 24
    Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. preclinical PubMed 22585736
  25. 25
    Maternal immune activation impairs endocannabinoid signaling in the mesolimbic system of adolescent male offspring. preclinical PubMed 36746342
  26. 26
    Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. preclinical PubMed 34384142
  27. 27
    Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method. preclinical PubMed 24346263
  28. 28
    Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination. preclinical PubMed 30075103
  29. 29
    Hexahydrocannabinol: pharmacokinetics, systemic toxicity, and acute behavioral effects in Wistar rats. preclinical PubMed 40643195
  30. 30
    Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice. preclinical PubMed 40176500
  31. 31
    Cannabigerol does not affect contextual fear memory in mice but modulates nociception in a sex-dependent manner. preclinical PubMed 40523564
  32. 32
    Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice. preclinical PubMed 39699828
  33. 33
    High Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome in an Inflammatory Bowel Disease Model. preclinical PubMed 39009468
  34. 34
    Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model. preclinical PubMed 40943856
  35. 35
    Cannabigerol as an anti-inflammatory agent altering the level of arachidonic acid derivatives in the colon tissue of rats subjected to a high-fat high-sucrose diet. preclinical PubMed 39128189
  36. 36
    Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation. preclinical PubMed 32996187
  37. 37
    Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. preclinical PubMed 27503475
  38. 38
    A cannabigerol-rich Cannabis sativa extract, devoid of [INCREMENT]9-tetrahydrocannabinol, elicits hyperphagia in rats. preclinical PubMed 28125508
  39. 39
    Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol. preclinical PubMed 31035309
  40. 40
    Ensiling conditions and changes of cannabinoid concentration in industrial hemp. preclinical PubMed 39192735
  41. 41
    Antinociceptive Effects of Cannabichromene (CBC) in Mice: Insights from von Frey, Tail-Flick, Formalin, and Acetone Tests. preclinical PubMed 38255191
  42. 42
    Biological activity of cannabichromene, its homologs and isomers. preclinical PubMed 7298870
  43. 43
    Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. preclinical PubMed 20332000
  44. 44
    Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain. preclinical PubMed 42151379
  45. 45
    The analgesic paracetamol metabolite AM404 acts peripherally to directly inhibit sodium channels. preclinical PubMed 40465624
  46. 46
    A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence. preclinical PubMed 38052772
  47. 47
    Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. preclinical PubMed 15763177
  48. 48
    Dietary oleic acid contributes to the regulation of food intake through the synthesis of intestinal oleoylethanolamide. preclinical PubMed 36733808
  49. 49
    Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. preclinical PubMed 18316044
  50. 50
    Effects of repeated lysergic acid diethylamide (LSD) on the mouse brain endocannabinoidome and gut microbiome. preclinical PubMed 36316276
  51. 51
    Stearoylethanolamide interferes with retrograde endocannabinoid signalling and supports the blood-brain barrier integrity under acute systemic inflammation. preclinical PubMed 31881191
  52. 52
    N-Stearoylethanolamine Exerts Cardioprotective Effects in Old Rats. preclinical PubMed 38279735
  53. 53
    [Effects of N-stearoylethanolamine on the emotionality and learning ability of rats]. preclinical PubMed 25566671
  54. 54
    [Immunosuppressive characteristics of N-stearoylethanolamine a stable compound with cannabimimetic activity]. preclinical PubMed 18710028
  55. 55
    [Anti-inflammatory effect of N-stearoylethanolamine in experimental burn injury in rats]. preclinical PubMed 19873884
  56. 56
    Exploring the Utility of Hair Endocannabinoids for Monitoring Homeostasis in Bonobos. preclinical PubMed 33434116